Deidre Dalmas

Deidre Dalmas has over two decades of experience in the field of toxicology and safety assessment, primarily holding positions at GSK from April 2001 to March 2020, where roles included Scientific Director for US Investigative Safety and nonclinical safety project lead. Dalmas has led investigative safety and toxicology efforts, managed diverse scientific teams, and developed nonclinical safety packages, particularly in the Oncology Therapeutic Area. Following GSK, Dalmas became a Pharma Industry Representative for the HESI Emerging Systems Toxicology for the Assessment of Risk Committee in November 2021, leading critical workgroups and collaborating with leadership in the field. Dalmas holds a PhD in Pharmacology and Toxicology from the University of the Sciences in Philadelphia and a Master of Science in Molecular Pharmacology from Thomas Jefferson University.